136 related articles for article (PubMed ID: 31063157)
1. Clinical outcomes and plasma clot permeability and lysability in patients with venous thromboembolism on rivaroxaban: a cohort study.
Frączek P; Krzysztofik M; Stanisz A; Undas A
Pol Arch Intern Med; 2019 Jun; 129(6):377-385. PubMed ID: 31063157
[TBL] [Abstract][Full Text] [Related]
2. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
Janion-Sadowska A; Natorska J; Siudut J; Ząbczyk M; Stanisz A; Undas A
Thromb Haemost; 2017 Aug; 117(9):1739-1749. PubMed ID: 28771277
[TBL] [Abstract][Full Text] [Related]
3. Prothrombotic fibrin clot properties are associated with post-discharge venous thromboembolism in acutely ill medical patients.
Wójcik M; Zaręba L; Undas A
Thromb Res; 2019 Oct; 182():141-149. PubMed ID: 31479942
[TBL] [Abstract][Full Text] [Related]
4. Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
Mrozinska S; Cieslik J; Broniatowska E; Malinowski KP; Undas A
J Thromb Haemost; 2019 Nov; 17(11):1912-1922. PubMed ID: 31323706
[TBL] [Abstract][Full Text] [Related]
5. Effects of direct oral anticoagulants on thromboelastographic parameters and fibrin clot properties in patients with venous thromboembolism.
Kopytek M; Zabczyk M; Natorska J; Malinowski KP; Undas A
J Physiol Pharmacol; 2020 Feb; 71(1):. PubMed ID: 32350148
[TBL] [Abstract][Full Text] [Related]
6. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome.
Siudut J; Grela M; Wypasek E; Plens K; Undas A
J Thromb Haemost; 2016 Apr; 14(4):784-93. PubMed ID: 26786481
[TBL] [Abstract][Full Text] [Related]
7. Viscoelastic properties of plasma fibrin clots are similar in patients on rivaroxaban and vitamin K antagonists.
Kopytek M; Zabczyk M; Natorska J; Siudut J; Malinowski KP; Ptaszek P; Glajcar A; Goralczyk T; Undas A
J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31019123
[TBL] [Abstract][Full Text] [Related]
8. Clot regression effects of rivaroxaban in the treatment of venous thromboembolism in patients with cancer (CRERIT-VTE cancer): study protocol.
Takai S; Nakanishi N; Yokota I; Imai K; Yamada A; Kawasaki T; Okada T; Sawada T; Fujita H; Matoba S
BMJ Open; 2019 Nov; 9(11):e031698. PubMed ID: 31694850
[TBL] [Abstract][Full Text] [Related]
9. Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism.
Żuk J; Snarska-Drygalska A; Malinowski KP; Papuga-Szela E; Natorska J; Undas A
J Thromb Thrombolysis; 2019 Feb; 47(2):248-254. PubMed ID: 30684190
[TBL] [Abstract][Full Text] [Related]
10. Unfavorably altered plasma clot properties in women with a HERDOO2 score equal to or greater than 2 and prediction of recurrent venous thromboembolism.
Mrozińska S; Cieślik J; Broniatowska E; Undas A
Pol Arch Intern Med; 2018 Oct; 128(10):572-579. PubMed ID: 30113019
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
[TBL] [Abstract][Full Text] [Related]
13. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
14. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
15. Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.
Khorana AA; Berger JS; Wells PS; Seheult R; Ashton V; Laliberté F; Crivera C; Lejeune D; Schein J; Wildgoose P; Lefebvre P; Kaatz S
Clin Ther; 2017 Jul; 39(7):1396-1408. PubMed ID: 28645879
[TBL] [Abstract][Full Text] [Related]
16. Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.
Bott-Kitslaar DM; McBane RD; Casanegra AI; Houghton DE; Froehling DA; Vlazny DT; Ashrani AA; Hodge DO; Vargas ER; Bartlett MA; Saadiq RA; Daniels PR; Shields RC; Lenz CJ; Lang TR; Wysokinski WE
Mayo Clin Proc; 2019 Jul; 94(7):1242-1252. PubMed ID: 30737059
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
20. Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study.
Cieslik J; Mrozinska S; Broniatowska E; Undas A
Blood; 2018 Feb; 131(7):797-807. PubMed ID: 29242187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
